Safety and efficacy of Profermin&reg; to induce remission in ulcerative colitis

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 15

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Apr 21, 2012; 18(15): 1773-1780
Published online Apr 21, 2012. doi: 10.3748/wjg.v18.i15.1773

Table 4 Concomitant medications

	n (%)
Mesalamine oral
Alone	21 (54)
Combined with immunosuppressants	8 (21)
Mesalamine enema or suppository	6 (15)
Azathioprine or 6-mercaptopurine	3 (8)
Corticosteroids oral	0 (0)
Corticosteroids enema	1 (3)
Antibiotics	0 (0)
TNF-α inhibitors	3 (8)
None	3 (8)

TNF-α: Tumor necrosis factor alpha.

Citation: Krag A, Israelsen H, Ryberg BV, Andersen KK, Bendtsen F. Safety and efficacy of Profermin^® to induce remission in ulcerative colitis. World J Gastroenterol 2012; 18(15): 1773-1780
URL: https://www.wjgnet.com/1007-9327/full/v18/i15/1773.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i15.1773

Krag A, Israelsen H, Ryberg BV, Andersen KK, Bendtsen F. Safety and efficacy of Profermin^® to induce remission in ulcerative colitis. World J Gastroenterol 2012; 18(15): 1773-1780 [PMID: 22553401 DOI: 10.3748/wjg.v18.i15.1773]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.